<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701517</url>
  </required_header>
  <id_info>
    <org_study_id>TIRCAMPATH-alo 2002</org_study_id>
    <nct_id>NCT02701517</nct_id>
  </id_info>
  <brief_title>Cyclosporine Plus Methotrexate or Alemtuzumab</brief_title>
  <official_title>Randomized Trial of Cyclosporine + CAMPATH-1H (ALEMTUZUMAB) vs. Cyclosporine + METHOTREXATE in Patients Diagnosed With Mature B-cell Neoplasms - Chronic Lymphocytic Leukemia and Low-grade Lymphomas - Receiving Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study was to compare the efficacy of the procedure in terms of
      event-free survival between patients receiving cyclosporine (CsA) plus either alemtuzumab
      (CAMPATH-1H ) or methotrexate (MTX) after matched related donor allo-reduced intensity
      conditioning. Secondary aims were: 1. To compare the incidence of infections and
      transplant-related mortality between the two arms; 2. to compare the incidence of acute and
      chronic GVHD 3. to evaluate hematologic and immunologic reconstitution and evolution of
      chimerism and residual disease.

      Patients were randomly assigned to received cyclosporine plus alemtuzumab or cyclosporine
      plus MTX and were stratified according to diagnosis: Chronic lymphocytic leukemia or Low
      grade- non-Hodgkin's lymphoma.

      All patients received the same reduced-intensity conditioning (RIC) scheme based on
      fludarabine 150mg/m2 (30 mg/m2/day everyday from -8 to -4) plus melphalan 140mg/m2 (70
      mg/m2/day everyday from -3 to -2). Regarding the GVHD prophylaxis, patients in group 1 (n=17)
      received CsA 1 mg/kg intravenously starting on day -7 and 2/mg/Kg from day -1 plus
      alemtuzumab administered at a dose of 20 mg IV on -8 to -4 whereas in group 2 (n=23) pts
      received CsA at same doses as group 1 plus MTX given at a dose of 15 mg/m2 intravenously on
      days 1 and 10 mg/m2 on days 3, 6 and 11, followed by folinic acid rescue (15 mg in +1 and 10
      mg in +3, +6 and +11 intravenously every 6 hours for 4 doses starting 24 hours after each
      dose of MTX).

      Acute and chronic GVHD were similarly graded by established criteria [20, 21]. In patients
      receiving alemtuzumab, CsA was suspended by day +130. They also received donor lymphocyte
      infusion (DLI) at a dose of 1 x 107 cluster of differentiation 3 / kg on day +180 in case of
      active disease, persistence of minimal residual disease detected by flow cytometry or mixed
      chimerism and no GVHD. In case mixed chimerism, donor lymphocyte infusion was performed if
      patient hematopoiesis progressively increased. In patients receiving CsA + MTX, CsA was
      suspended by day +180. These patients received DLI only in situations specified above.

      The statistical analysis has been designed to identify a 20% difference in terms of
      disease-free survival (based on the increased incidence of relapse in patients receiving
      T-cell depletion).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was stopped before the targeted number of patients was reached due to lack of
    support.
  </why_stopped>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of transplantation in terms of event-free survival</measure>
    <time_frame>From +270 days</time_frame>
    <description>To compare the efficacy of transplantation in terms of event-free survival between patients receiving CAMPATH-1H or methotrexate in allogeneic related donor with nonmyeloablative conditioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections and transplant-related mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Compare the incidence of infections and transplant-related mortality between the two arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>incidence of graft versus host disease</measure>
    <time_frame>5 years</time_frame>
    <description>Analyze the impact on the incidence of graft versus host disease (GVHD) acute and chronic CAMPATH-1H + DLI compared with MTX as GVHD prophylaxis in allogeneic related donor with nonmyeloablative conditioning.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Unrecognized Condition: Mature B or T-cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Cyclosporine + METHOTREXATE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX days +1, +3, +6 and +11 followed by folinic acid rescue. All patients will receive CSA from day -7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine + CAMPATH-1H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine + METHOTREXATE</intervention_name>
    <description>MTX days +1, +3, +6 and +11 followed by rescue with folinic Ac. All patients receive CSA from day -7.</description>
    <arm_group_label>Cyclosporine + METHOTREXATE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine + CAMPATH-1H</intervention_name>
    <description>CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.</description>
    <arm_group_label>Cyclosporine + CAMPATH-1H</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Having an identical Human Leukocyte Antigens (HLA) or a mismatched family donor.

          2. Age between 45 and 65 years (outside this age range at the discretion of each center).

          3. Indications:

               -  Follicular lymphoma with one of the following characteristics:

                    1. Poor prognosis follicular NHL (3 or more factors by Federico et al:
                       erythrocyte sedimentation rate (ESR)&gt; 30, male,&gt; 60 years, high LDH&gt; 2
                       extranodal areas, pathologic stage (PS) &gt;2 or The International Prognostic
                       Index (IPI) 3 or high lactate dehydrogenase (LDH) or micro Beta 2) failing
                       to achieve CR with regimens including fludarabine and anti CD20 (cluster of
                       differentiation antigen 20 ).

                    2. 2nd CR (complete response) or PR (partial response) not candidates for
                       autologous transplantation;

                    3. persistent disease or relapse after autologous transplantation.

               -  Other low-grade lymphomas:

                    1. relapsed after autologous transplantation.

                    2. autologous transplant candidates which can not be performed because of the
                       inability to collect a sufficient number of cells, steam cells disease
                       persistence, etc..

               -  Chronic lymphocytic leukemia with one of the following characteristics:

                    1. &quot;B&quot; symptoms: weight loss &gt;10% in the last 6 months, fever &gt;38ºC (degrees
                       centigrade) for 14 days without infection, night sweats without infection

                    2. lymphadenopathy &gt;10 cm or progressive, progressive splenomegaly

                    3. Anemia and/or thrombocytopenia secondary to bone marrow infiltration

                    4. Diffuse lymphocytic infiltration of the bone marrow

                    5. Progressive lymphocytosis (&gt;50% in 2 months) or a lymphocyte doubling time
                       &lt;12 months Any of the above criteria is an inclusion criteria in the
                       protocol in patients who have received at least one line of treatment
                       including fludarabine

                    6. Patients with poor prognostic cytogenetic abnormalities: 17p-, 11q-with VDJ
                       unmutated

          4. Patients must also meet the following general requirements:

               1. Performance status &lt;3 (Zubrod score, Eastern Cooperative Oncology Group (ECOG)
                  performance status or WHO (World Health Organization) )

               2. forced expiratory volume at one second (FEV1) &gt; 39%, lung diffusing capacity for
                  carbon monoxide (DLCO) and forced vital capacity (FVC) &gt; 39% of the theoretical
                  values

               3. Total bilirubin and transaminases &lt;3 x the normal maximum value, unless
                  attributable to base haemopathy

               4. Creatinine &lt;2 x normal maximum and clearance&gt; 40 mL / min unless attributable to
                  his base haemopathy

               5. No evidence of symptomatic disease, cirrhosis or active hepatitis

               6. Negative serology for HIV

               7. Written informed consent

        Exclusion criteria:

          1. Impaired hepatic or renal function superior to that described above

          2. Presence of serious diseases that prevent chemotherapy treatments

          3. Presence of psychiatric comorbidity

          4. HIV infection

          5. Other prior neoplasm

          6. Do not have signed informed consent

          7. Pregnant or at risk of pregnancy by inadequate contraceptive measures.

          8. Patients diagnosed with chronic lymphocytic leukemia (CLL) transformation to more
             aggressive cytologic or histologic forms (prolymphocytic leukemia, large cell
             lymphoma, Hodgkin's disease) and those affected with autoimmune hemolytic anemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Antonio Pérez-Simón, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Propedeutic Oncology, Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hematology Department. ICO-Hospital Germans Trias i Pujol. Jose Carreras Research Institute</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Creu I Sant Pau Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI; Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol. 2005 Jun;129(5):631-43.</citation>
    <PMID>15916686</PMID>
  </reference>
  <reference>
    <citation>Chen PM, Tzeng CH, Fan FS, Hsieh RK, Wei CH. Bone marrow transplantation in Taiwan: low incidence of acute GVHD in patients with hematologic malignancies and severe aplastic anemia. Bone Marrow Transplant. 1994 Jun;13(6):709-11.</citation>
    <PMID>7920299</PMID>
  </reference>
  <reference>
    <citation>Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995 Jun;15(6):825-8. Review.</citation>
    <PMID>7581076</PMID>
  </reference>
  <reference>
    <citation>Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981 Feb;57(2):267-76.</citation>
    <PMID>7004534</PMID>
  </reference>
  <reference>
    <citation>Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004 Dec 15;104(13):3865-71. Epub 2004 Aug 10.</citation>
    <PMID>15304395</PMID>
  </reference>
  <reference>
    <citation>Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97. doi: 10.1016/j.bbmt.2008.09.001.</citation>
    <PMID>18940684</PMID>
  </reference>
  <reference>
    <citation>Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002 Nov 1;100(9):3121-7.</citation>
    <PMID>12384408</PMID>
  </reference>
  <reference>
    <citation>Martino R, Caballero MD, Canals C, Simón JA, Solano C, Urbano-Ispízua A, Bargay J, Rayón C, Léon A, Sarrá J, Odriozola J, Conde JG, Sierra J, San Miguel J; ALLOPBSCT Subcommittee of the Spanish Group for Haematopoietic Transplantation (GETH); Group GEL-TAMO. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol. 2001 Dec;115(3):653-9.</citation>
    <PMID>11736950</PMID>
  </reference>
  <reference>
    <citation>Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009 Jan;144(1):95-8. doi: 10.1111/j.1365-2141.2008.07394.x. Epub 2008 Oct 30.</citation>
    <PMID>19016732</PMID>
  </reference>
  <reference>
    <citation>Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 May 15;99(10):3554-61.</citation>
    <PMID>11986207</PMID>
  </reference>
  <reference>
    <citation>Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002 Sep 15;20(18):3891-7.</citation>
    <PMID>12228210</PMID>
  </reference>
  <reference>
    <citation>Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997 Apr;15(4):1567-74.</citation>
    <PMID>9193354</PMID>
  </reference>
  <reference>
    <citation>Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002 Jun 15;99(12):4357-63.</citation>
    <PMID>12036862</PMID>
  </reference>
  <reference>
    <citation>Hale G, Cobbold S, Novitzky N, Bunjes D, Willemze R, Prentice HG, Milligan D, MacKinnon S, Waldmann H; CAMPATH Users. CAMPATH-1 antibodies in stem-cell transplantation. Cytotherapy. 2001;3(3):145-64.</citation>
    <PMID>12171722</PMID>
  </reference>
  <reference>
    <citation>Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000 Oct 1;96(7):2419-25.</citation>
    <PMID>11001893</PMID>
  </reference>
  <reference>
    <citation>Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S, Mehra RC, Vriesendorp HM, Andersson BS, Giralt S, Körbling M, Keating MJ, Champlin RE. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May;97(2):466-73.</citation>
    <PMID>9163617</PMID>
  </reference>
  <reference>
    <citation>Rondón G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 1996 Sep;18(3):669-72.</citation>
    <PMID>8879640</PMID>
  </reference>
  <reference>
    <citation>van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal OK, Gale RP, Klein JP, Lazarus HM, McCarthy PL Jr, Raemaekers JM, Reiffers J, Phillips GL, Schattenberg AV, Verdonck LF, Vose JM, Horowitz MM. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998 Sep 1;92(5):1832-6.</citation>
    <PMID>9716615</PMID>
  </reference>
  <reference>
    <citation>Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug;16(8):2817-24.</citation>
    <PMID>9704734</PMID>
  </reference>
  <reference>
    <citation>Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 1;97(3):631-7.</citation>
    <PMID>11157478</PMID>
  </reference>
  <reference>
    <citation>Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756-63.</citation>
    <PMID>9446633</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>conditioning treatment</keyword>
  <keyword>alemtuzumab</keyword>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>chronic lymphoproliferative disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

